The dual PPARα/γ agonist aleglitazar increases the number and function of endothelial progenitor cells: implications for vascular function and atherogenesis

The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors

(2013) Stephen P.H. Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Essential role of interleukin-6 in post-stroke angiogenesis

(2012) Karen Gertz et al.   BRAIN

Comparative Molecular Profiling of the PPARα/γ Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors

(2012) Michel Dietz et al.   ChemMedChem

Critical Reevaluation of Endothelial Progenitor Cell Phenotypes for Therapeutic and Diagnostic Use

(2012) Gian Paolo Fadini et al.   CIRCULATION RESEARCH

From Bench to Bedside: What Physicians Need to Know About Endothelial Progenitor Cells

(2011) Mayr Matthias et al.   AMERICAN JOURNAL OF MEDICINE

Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis

(2011) Christian Werner et al.   ATHEROSCLEROSIS

Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome

(2011) Barbara C Hansen et al.   Cardiovascular Diabetology

Hyperglycemia in apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility

(2011) Jing Li et al.   Cardiovascular Diabetology

Heart-rate reduction by If-channel inhibition with ivabradine restores collateral artery growth in hypercholesterolemic atherosclerosis

(2011) Stephan H. Schirmer et al.   EUROPEAN HEART JOURNAL

Galectin-2 expression is dependent on the rs7291467 polymorphism and acts as an inhibitor of arteriogenesis

(2011) Anja M. van der Laan et al.   EUROPEAN HEART JOURNAL

Effects of DPP-4 inhibition on cardiac metabolism and function in mice

(2011) M. Lenski et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ Agonist

(2010) Matthew A. Cavender et al.   American Journal of Cardiovascular Drugs

Regulation of Bone Marrow-Derived Vascular Progenitor Cell Mobilization and Maintenance

(2010) Stefanie Dimmeler   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

The renin inhibitor aliskiren upregulates pro-angiogenic cells and reduces atherogenesis in mice

(2010) Janine Pöss et al.   BASIC RESEARCH IN CARDIOLOGY

Guidelines for reporting experiments involving animals: the ARRIVE guidelines

(2010) JC McGrath et al.   BRITISH JOURNAL OF PHARMACOLOGY

Animal research: Reporting in vivo experiments: The ARRIVE guidelines

(2010) Carol Kilkenny et al.   BRITISH JOURNAL OF PHARMACOLOGY

Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2

(2010) Saher Hamed et al.   CARDIOVASCULAR RESEARCH

The Promise of Cell-Based Therapies for Diabetic Complications

(2010) Yagna P.R. Jarajapu et al.   CIRCULATION RESEARCH

Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes: Results From a Randomized, Placebo-Controlled Clinical Study

(2010) P Sanwald-Ducray et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effects of high dose aleglitazar on renal function in patients with type 2 diabetes

(2010) Matthias Herz et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease

(2010) Giovanni Targher et al.   NEW ENGLAND JOURNAL OF MEDICINE

PPARα Is Essential for Microparticle-Induced Differentiation of Mouse Bone Marrow-Derived Endothelial Progenitor Cells and Angiogenesis

(2010) Tarek Benameur et al.   PLoS One

Peroxisome Proliferator-Activated Receptor Alpha Target Genes

(2010) Maryam Rakhshandehroo et al.   PPAR Research

Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes

(2009) Agnes Bénardeau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Physical Exercise Prevents Cellular Senescence in Circulating Leukocytes and in the Vessel Wall

(2009) Christian Werner et al.   CIRCULATION

Stimulation of collateral artery growth: travelling further down the road to clinical application

(2009) S H Schirmer et al.   HEART

PPAR-α and PPAR-γ agonists for type 2 diabetes

(2009) Bernard Charbonnel   LANCET

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

Heart Rate Reduction by Ivabradine Reduces Oxidative Stress, Improves Endothelial Function, and Prevents Atherosclerosis in Apolipoprotein E–Deficient Mice

(2008) Florian Custodis et al.   CIRCULATION

Rapid Endothelial Turnover in Atherosclerosis-Prone Areas Coincides With Stem Cell Repair in Apolipoprotein E–Deficient Mice

(2008) Georgios Foteinos et al.   CIRCULATION

Interferon-β Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice

(2008) Stephan H. Schirmer et al.   CIRCULATION RESEARCH

Effects of Physical Exercise on Myocardial Telomere-Regulating Proteins, Survival Pathways, and Apoptosis

(2008) Christian Werner et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY